Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Brain Behav Immun ; 66: 125-134, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28733081

RESUMO

OBJECTIVE: To study the prevalence of autoantibodies to synapsin in patients with psychiatric and neurological disorders and to describe clinical findings in synapsin antibody positive patients. METHODS: Sera of 375 patients with different psychiatric and neurological disorders and sera of 97 healthy controls were screened (dilution 1:320) for anti-synapsin IgG using HEK293 cells transfected with rat synapsin Ia. Positive sera were further analyzed by immunoblots with brain tissue from wild type and synapsin knock out mice and with HEK293 cells transfected with human synapsin Ia and Ib. Binding of synapsin IgG positive sera to primary neurons was studied using murine hippocampal neurons. RESULTS: IgG in serum from 23 (6.1%) of 375 patients, but from none of the 97 healthy controls (p=0.007), bound to rat synapsin Ia transfected cells with a median (range) titer of 1:1000 (1:320-1:100,000). Twelve of the 23 positive sera reacted with a protein of the molecular size of synapsin I in immunoblots of wild type but not of synapsin knock out mouse brain tissue. Out of 19/23 positive sera available for testing, 13 bound to human synapsin Ia and 16 to human synapsin Ib transfected cells. Synapsin IgG positive sera stained fixed and permeabilized murine hippocampal neurons. Synapsin IgG positive patients had various psychiatric and neurological disorders. Tumors were documented in 2 patients (melanoma, small cell lung carcinoma); concomitant anti-neuronal or other autoantibodies were present in 8 patients. CONCLUSIONS: Autoantibodies to human synapsin Ia and Ib are detectable in a proportion of sera from patients with different psychiatric and neurological disorders, warranting further investigation into the potential pathophysiological relevance of these antibodies.


Assuntos
Autoanticorpos/sangue , Transtornos Mentais/imunologia , Doenças do Sistema Nervoso/imunologia , Sinapsinas/sangue , Sinapsinas/imunologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Criança , Feminino , Células HEK293 , Hipocampo/metabolismo , Humanos , Imunoglobulina G/sangue , Masculino , Transtornos Mentais/sangue , Transtornos Mentais/epidemiologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Pessoa de Meia-Idade , Doenças do Sistema Nervoso/sangue , Doenças do Sistema Nervoso/epidemiologia , Neurônios/metabolismo , Prevalência , Ratos , Adulto Jovem
2.
J Pediatr Endocrinol Metab ; 29(3): 297-303, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26587741

RESUMO

BACKGROUND: Pituitary hyperplasia secondary to primary longstanding hypothyroidism has been reported in the literature in adults and rarely in children. METHODS: Here we present the clinical presentation and diagnostic procedures in eight children with pituitary hyperplasia due to autoimmune thyroiditis, highlighting common findings, such as growth delay, fatigue or gaining weight, but also exceptional findings such as pericardial effusion, rhabdomyolysis, isolated hypertrichosis, and Van Wyk-Grumbach syndrome, which have rarely or never been described. RESULTS AND CONCLUSIONS: Surprisingly no thyroid enlargement was detected. We discuss the unusual presenting signs of autoimmune thyroiditis that should raise the suspicion of pituitary hyperplasia. We suggest that a more elaborate clinical assessment and even modification of the diagnostic approach to autoimmune thyroiditis is needed in order to avoid its serious complications.


Assuntos
Doença de Hashimoto/diagnóstico , Hiperplasia/diagnóstico , Hipotireoidismo/complicações , Doenças da Hipófise/diagnóstico , Tireoidite Autoimune/diagnóstico , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Seguimentos , Doença de Hashimoto/diagnóstico por imagem , Doença de Hashimoto/etiologia , Humanos , Hiperplasia/diagnóstico por imagem , Hiperplasia/etiologia , Imageamento por Ressonância Magnética , Masculino , Doenças da Hipófise/diagnóstico por imagem , Doenças da Hipófise/etiologia , Prognóstico , Estudos Retrospectivos , Tireoidite Autoimune/diagnóstico por imagem , Tireoidite Autoimune/etiologia , Adulto Jovem
3.
BMC Endocr Disord ; 15: 82, 2015 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-26666878

RESUMO

BACKGROUND: Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder with an extremely variable phenotype. In childhood NF1 can be associated with optic glioma and central precocious puberty; the latter is more common when the optic chiasm is affected. The mutational spectrum of the NF1 gene is wide and complex; R681X is a rare severe mutation of the NF1 gene known to cause truncation of neurofibromin, with only ten reported cases in the literature so far. CASE PRESENTATION: We describe a girl with NF1 associated with early central precocious puberty appearing at 2.5 years of age and optic glioma affecting the optic chiasm as seen on magnetic resonance imaging (MRI). Genetic analysis confirmed the presence of R681X. Therapy with a gonadotropin-releasing hormone agonist was instituted with good response to therapy. The lesions on MRI were stable and no significant vision impairment was present during the 6 years of follow-up. CONCLUSION: Of the ten reported cases of NF1 due to R681X, one has presented with optic glioma and none with precocious puberty. Thus, to our knowledge, this is the first reported case of this mutation presenting with precocious puberty. We believe that this is a contribution to the few reports on the phenotype of this mutation and to the future elucidation of genotype-phenotype correlations of this disease.


Assuntos
Hormônio Liberador de Gonadotropina/agonistas , Mutação , Neurofibromatose 1/patologia , Neurofibromina 1/genética , Glioma do Nervo Óptico/patologia , Puberdade Precoce/tratamento farmacológico , Pamoato de Triptorrelina/uso terapêutico , Arginina , Pré-Escolar , Feminino , Humanos , Imageamento por Ressonância Magnética , Neurofibromatose 1/complicações , Neurofibromatose 1/tratamento farmacológico , Neurofibromatose 1/genética , Glioma do Nervo Óptico/tratamento farmacológico , Glioma do Nervo Óptico/genética , Puberdade Precoce/etiologia , Puberdade Precoce/genética , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA